Abbott Laboratories
$91.7M 292,558 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation reported $92,997,632.79 across General Payments, Research, and Ownership to 70,149 physicians and teaching hospitals across 75,191 transactions.
- $93.0M
- All-tracks total
- 75,191
- Transactions
- 70,149
- Recipients
- +$11.5M
- General Payments vs PY2023
Edwards Lifesciences Corporation reported $92,997,632.79 across all CMS Open Payments tracks (General + Research + Ownership) to 70,149 physicians and teaching hospitals in Program Year 2024 - ranking #29 of 1,925 reporting manufacturers (0.7% of the all-tracks industry total); General Payments alone were $27,843,957.70, averaging $1.3K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer edwards-lifesciences-corporation Edwards Lifesciences Corporation
$93.0M · #29/1,925 · 0.7% industry · PY2024
- TOT $93.0M
- RANK #29
- SHARE 0.7%
- TXN 75,191
- RCP 70,149
- CAT 12
- GEN $27.8M
- ΔGEN +$11.5M
- TOP1 16.8%
- PY 2024
Volume peers
Nearest volume peer: Abbott Laboratories ($91.7M)
Edwards Lifesciences Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Edwards Lifesciences Corporation's CMS-reported General Payments increased by $11.5M (+70.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: EDWARDS LIFESCIENCES CORPORATIONPY2023: EDWARDS LIFESCIENCES CORPORATIONPY2024: Edwards Lifesciences Corporation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $16,328,082.28
- PY2024
- $27,843,957.70
What the Data Shows for Edwards Lifesciences Corporation
Averaging $1.2K per transaction and $1.3K per recipient, Edwards Lifesciences Corporation's Program Year 2024 total comes to $92,997,632.79 across 75,191 transactions and 70,149 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #29 of 1,925 companies, representing 0.7% of all industry payments reported nationwide for the year.
The 12-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Acquisitions" at $8.0M, accounting for 28.9% of this company's General Payments and 23 transactions.
General Payment Breakdown by Type
"Acquisitions" leads Edwards Lifesciences Corporation's 12-category general-payment breakdown at $8.0M, 28.9% of the reported total.
Edwards Lifesciences Corporation reports 12 general-payment categories - the top three are Acquisitions (28.9%), Consulting Fee (28.2%), and Food and Beverage (11.2%). The remaining 9 categories make up 31.8% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Edwards Lifesciences Corporation files across 12 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Edwards Lifesciences Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Acquisitions | $8.0M | 23 | 28.9% |
| Consulting Fee | $7.8M | 2,429 | 28.2% |
| Food and Beverage | $3.1M | 58,091 | 11.2% |
| Travel and Lodging | $2.8M | 8,679 | 10.0% |
| Royalty or License | $1.6M | 12 | 5.6% |
| Grant | $1.4M | 67 | 5.1% |
| Compensation for Services Other Than Consulting | $1.2M | 260 | 4.1% |
| Debt Forgiveness | $1.1M | 6 | 3.9% |
| Space Rental or Facility Fees | $453.0K | 96 | 1.6% |
| Charitable Contribution | $370.0K | 2 | 1.3% |
| Education | $15.3K | 472 | 0.1% |
| Long-Term Medical Supply or Device Loan | $8.9K | 12 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $8,229,235.74 (29.6%) of $27,843,957.70 in this company's General Payments records across 19,598 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Edwards Lifesciences Corporation
The five named recipients with the highest reported General Payments from this company
- 1
Anthony Nunez
$4,670,831.35 across 3 reported transactions
- 2
Cleveland Clinic Hospital
$1,560,432.00 across 6 reported transactions
- 3
Nicolas Chronos
$889,686.38 across 5 reported transactions
- 4
Steward St. Elizabeths Medical Ctr
$635,203.90 across 1 reported transactions
- 5
Charanjit Rihal
$473,082.11 across 2 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Edwards Lifesciences Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Edwards Lifesciences Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Edwards Lifesciences Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Genzyme Corporation
$97.0M 182,526 recipients
Compare payment profiles
Celgene Corporation
$88.9M 60,850 recipients
Compare payment profiles
Zimmer Biomet Holdings, Inc.
$88.6M 33,496 recipients
Compare payment profiles
CSL Behring
$88.2M 27,644 recipients
Compare payment profiles
Boston Scientific Corporation
$99.8M 271,484 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.